 Angiotensin II
"Angiotensin II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
| Descriptor ID |
D000804
|
| MeSH Number(s) |
D06.472.699.094.078 D12.644.400.070.078 D12.644.456.073.041 D12.644.548.058.078 D12.776.641.650.070.078 D23.469.050.050.050
|
| Concept/Terms |
Angiotensin II- Angiotensin II
- Angiotensin-(1-8) Octapeptide
- ANG-(1-8)Octapeptide
Angiotensin II, Ile(5)-- Angiotensin II, Ile(5)-
- Isoleucyl(5)-Angiotensin II
- Isoleucine(5)-Angiotensin
- 5-L-Isoleucine Angiotensin II
- 5 L Isoleucine Angiotensin II
- Angiotensin II, 5-L-Isoleucine
- II, 5-L-Isoleucine Angiotensin
- Angiotensin II, Isoleucine(5)-
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II".
This graph shows the total number of publications written about "Angiotensin II" by people in UAMS Profiles by year, and whether "Angiotensin II" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2021 | 0 | 2 | 2 | | 2019 | 2 | 1 | 3 | | 2018 | 1 | 2 | 3 | | 2017 | 1 | 1 | 2 | | 2016 | 1 | 3 | 4 | | 2015 | 2 | 2 | 4 | | 2014 | 3 | 3 | 6 | | 2013 | 4 | 1 | 5 | | 2012 | 4 | 3 | 7 | | 2011 | 0 | 2 | 2 | | 2010 | 5 | 2 | 7 | | 2009 | 1 | 1 | 2 | | 2008 | 2 | 4 | 6 | | 2007 | 5 | 3 | 8 | | 2006 | 4 | 2 | 6 | | 2005 | 4 | 1 | 5 | | 2004 | 4 | 4 | 8 | | 2003 | 3 | 3 | 6 | | 2002 | 3 | 6 | 9 | | 2001 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 1998 | 3 | 2 | 5 | | 1997 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin II" by people in Profiles over the past ten years.
-
Althammer F, Roy RK, Kirchner MK, Campos-Lira E, Whitley KE, Davis S, Montanez J, Ferreira-Neto HC, Danh J, Feresin R, Biancardi VC, Zafar U, Parent MB, Stern JE. Angiotensin II-Mediated Neuroinflammation in the Hippocampus Contributes to Neuronal Deficits and Cognitive Impairment in Heart Failure Rats. Hypertension. 2023 06; 80(6):1258-1273.
-
Van Hoose PM, Yang L, Kraemer M, Ubele M, Morris AJ, Smyth SS. Lipid phosphate phosphatase 3 in smooth muscle cells regulates angiotensin II-induced abdominal aortic aneurysm formation. Sci Rep. 2022 04 05; 12(1):5664.
-
Babaahmadi-Rezaei H, Rezaei M, Ghaderi-Zefrehi H, Azizi M, Beheshti-Nasab H, Mehta JL. Reducing Proteoglycan Synthesis and NOX Activity by ROCK Inhibitors: Therapeutic Targets in Atherosclerosis. Endocr Metab Immune Disord Drug Targets. 2022; 22(12):1191-1200.
-
Ozkizilcik A, Sysavanh F, Patel S, Tandon I, Balachandran K. Local Renin-Angiotensin System Signaling Mediates Cellular Function of Aortic Valves. Ann Biomed Eng. 2021 Dec; 49(12):3550-3562.
-
Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, Liu J, Harville TO. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021; 16(9):e0257016.
-
Thirugnanam K, Cossette SM, Lu Q, Chowdhury SR, Harmann LM, Gupta A, Spearman AD, Sonin DL, Bordas M, Kumar SN, Pan AY, Simpson PM, Strande JL, Bishop E, Zou MH, Ramchandran R. Cardiomyocyte-Specific Snrk Prevents Inflammation in the Heart. J Am Heart Assoc. 2019 11 19; 8(22):e012792.
-
Vackov? ?, Kikerlov? S, Melenovsky V, Kol?r F, Imig JD, Kompanowska-Jezierska E, Sadowski J, Cervenka L. Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure. Kidney Blood Press Res. 2019; 44(4):792-809.
-
Reyes-Pardo H, Bautista R, Vargas-Robles H, Rios A, S?nchez D, Escalante B. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage. BMC Nephrol. 2019 08 02; 20(1):292.
-
Imig JD. Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction. Acta Physiol (Oxf). 2019 01; 225(1):e13203.
-
Sedl?kov? L, Kikerlov? S, Huskov? Z, Cervenkov? L, Ch?bov? VC, Zicha J, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kr?tk? V, Cervenka L, Kopkan L. 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Biosci Rep. 2018 10 31; 38(5).
-
Cervenka L, Huskov? Z, Kopkan L, Kikerlov? S, Sedl?kov? L, Vanourkov? Z, Al?nov? P, Kol?r F, Hammock BD, Hwang SH, Imig JD, Falck JR, Sadowski J, Kompanowska-Jezierska E, Neck?r J. Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension. J Hypertens. 2018 06; 36(6):1326-1341.
-
Kenchegowda D, Legesse B, Hritzo B, Olsen C, Aghdam S, Kaur A, Culp W, Derrien-Colemyn A, Severson G, Moroni M. Selective Insulin-like Growth Factor Resistance Associated with Heart Hemorrhages and Poor Prognosis in a Novel Preclinical Model of the Hematopoietic Acute Radiation Syndrome. Radiat Res. 2018 08; 190(2):164-175.
-
Salazar G, Huang J, Feresin RG, Zhao Y, Griendling KK. Zinc regulates Nox1 expression through a NF-?B and mitochondrial ROS dependent mechanism to induce senescence of vascular smooth muscle cells. Free Radic Biol Med. 2017 07; 108:225-235.
-
Perez J, Diaz N, Tandon I, Plate R, Martindale C, Balachandran K. Elevated Serotonin Interacts with Angiotensin-II to Result in Altered Valve Interstitial Cell Contractility and Remodeling. Cardiovasc Eng Technol. 2018 06; 9(2):168-180.
-
Feresin RG, Huang J, Klarich DS, Zhao Y, Pourafshar S, Arjmandi BH, Salazar G. Blackberry, raspberry and black raspberry polyphenol extracts attenuate angiotensin II-induced senescence in vascular smooth muscle cells. Food Funct. 2016 Oct 12; 7(10):4175-4187.
-
J?chov? ?, Kopkan L, Huskov? Z, Dole?elov? ?, Neck?r J, Kujal P, Vernerov? Z, Kramer HJ, Sadowski J, Kompanowska-Jezierska E, Reddy RN, Falck JR, Imig JD, Cervenka L. Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2016 10; 34(10):2008-25.
-
Tarantini S, Tucsek Z, Valcarcel-Ares MN, Toth P, Gautam T, Giles CB, Ballabh P, Wei JY, Wren JD, Ashpole NM, Sonntag WE, Ungvari Z, Csiszar A. Circulating IGF-1 deficiency exacerbates hypertension-induced microvascular rarefaction in the mouse hippocampus and retrosplenial cortex: implications for cerebromicrovascular and brain aging. Age (Dordr). 2016 Aug; 38(4):273-289.
-
Wang XW, Zhang FX, Yang F, Ding ZF, Agarwal N, Guo ZK, Mehta JL. Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro. Acta Pharmacol Sin. 2016 Sep; 37(10):1349-1358.
-
Stec DE, Juncos LA, Granger JP. Renal intramedullary infusion of tempol normalizes the blood pressure?response to intrarenal blockade of heme oxygenase-1 in?angiotensin II-dependent hypertension. J Am Soc Hypertens. 2016 Apr; 10(4):346-51.
-
Bagchi RA, Mozolevska V, Abrenica B, Czubryt MP. Development of a high throughput luciferase reporter gene system for screening activators and repressors of human collagen Ia2 gene expression. Can J Physiol Pharmacol. 2015 Oct; 93(10):887-92.
-
Ding Z, Liu S, Wang X, Khaidakov M, Fan Y, Deng X, Xiang D, Mehta JL. Lectin-like oxidized low-density lipoprotein receptor-1 regulates autophagy and Toll-like receptor 4 in the brain of hypertensive mice. J Hypertens. 2015 Mar; 33(3):525-33; discussion 533.
-
Zawada WM, Mrak RE, Biedermann J, Palmer QD, Gentleman SM, Aboud O, Griffin WS. Loss of angiotensin II receptor expression in dopamine neurons in Parkinson's disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation. Acta Neuropathol Commun. 2015 Feb 03; 3:9.
-
Mehta JL, Mercanti F, Stone A, Wang X, Ding Z, Romeo F, Khaidakov M. Gene and microRNA transcriptional signatures of angiotensin II in endothelial cells. J Cardiovasc Pharmacol. 2015 Feb; 65(2):123-9.
-
Sporkov? A, J?chov? S, Huskov? Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2014 Dec; 41(12):1003-13.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|